2016_Head & Neck COURSE BOOK

First page Previous page 472-473 Next page Last page

DAHANCA19: Loco‐regional control

control 77%

zalutumumab 76%

HR: 1.14 [95% CI: 0.81‐1.59]

Pts. at risk Events

zalutumumab.

301 307 608

70 63

control

total

133

Eriksen, H&N Arizona 2014

Made with